Proton Pump Inhibitor Use and Asthma Flares - AMJ

This site is intended for healthcare professionals

Chronic Proton Pump Inhibitor Use Linked to Asthma Flares

Author:
Clinician reviews a prescription bottle with an adult patient during an asthma follow-up visit.

Key Summary:

  • Asthma exacerbations occurred in 31.9% of PPI users and 22.6% of nonusers over 1 year.
  • PPI users had higher rates of rescue steroid use, respiratory infections, and emergency visits.
  • The findings support reviewing whether long-term PPI therapy still has a clear indication.

CHRONIC proton pump inhibitor use was linked to more asthma exacerbations in adults with difficult-to-treat asthma using biologics. In a matched U.S. cohort presented at the CHEST 2026 Annual Meeting, patients who used proton pump inhibitors (PPIs) also had higher rates of rescue systemic corticosteroid use, respiratory infections, and emergency visits over 1 year.

Proton Pump Inhibitor Use and Asthma Exacerbations

The retrospective study drew on records from 65 U.S. health care organizations and included adults who received biologic therapy for asthma between 2014 and 2025. Researchers excluded patients with established indications for acid suppression, including documented gastroesophageal reflux disease, Barrett’s esophagus, and peptic ulcer disease, to focus on empiric proton pump inhibitor use.

Researchers identified persistent use through repeat prescriptions and used propensity score matching to balance measured characteristics, including prior exacerbations, asthma severity markers, and medication exposure. After matching, each group included 1,228 patients. Asthma exacerbations occurred in 31.9% of PPI users and 22.6% of nonusers, an absolute difference of 9.3 percentage points (odds ratio [OR], 1.60; 95% CI, 1.34–1.92).

Higher Steroid Use and More Emergency Visits

Rescue systemic corticosteroid use showed the largest absolute difference among reported outcomes, occurring in 72% of PPI users and 40% of nonusers. Respiratory infections occurred in 8.4% and 2.3%, respectively. Intensive care unit admissions (4.3% vs 1.2%) and emergency visits (15.6% vs 8.4%) were also more common among PPI users. All-cause mortality did not differ significantly between groups.

Reviewing the Indication for Long-Term Acid Suppression

Because this was a retrospective study, differences that were unmeasured or incompletely captured could still contribute to the observed associations. The researchers proposed that changes in the microbiome could increase susceptibility to respiratory pathogens, a hypothesis that the study did not test.

For clinicians reviewing medications when asthma exacerbations persist during biologic therapy, the findings highlight a practical question: Does the original indication for long-term acid suppression still apply? The investigators emphasized documenting the indication and considering structured deprescribing when ongoing PPI therapy has no clear clinical indication.

Reference
Le JP et al. Empiric chronic proton pump inhibitor use is associated with increased exacerbations in biologic-treated difficult-to-treat asthma: a propensity-matched US cohort study. CHEST Annual Meeting, October 18–21, 2026.

Featured Image: kamiphotos on Adobe Stock.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.